---
schema_version: "secwatch.filing_event.v1"
accession: "0001528287-21-000017"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:52:52.673224+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroPace Q3 revenue drops 19% to $10.3M; net loss widens to $8.1M

## Summary
- Q3 total revenue $10.3M down 19% YoY; initial implant revenue $7.8M down 15%.
- Net loss $8.1M vs $4.1M loss in prior year; gross margin 72.6% vs 75.0%.
- Updated FY2021 guidance: total revenue $44-44.5M (7-8% growth), initial implant $33-33.5M.
- Received IDE approval for clinical study to expand indication to primary generalized epilepsy.
- Added Lisa Andrade to Board; submitted PMA supplement for longer battery life claim (nearly 11 yrs).

## SEC filing metadata
- accession: 0001528287-21-000017
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000152828721000017/0001528287-21-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000152828721000017/npce-20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001528287-21-000017
- JSON: https://secwatch.observer/filing/0001528287-21-000017.json
- Plain text: https://secwatch.observer/filing/0001528287-21-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.